Abstract
To evaluate the clinical utility of pioglitazone therapy in patients who previously received troglitazone. We undertook an observational study involving patients with type 2 diabetes, who were originally treated with troglitazone and subsequently converted to pioglitazone therapy. Drug efficacy was evaluated by comparing baseline hemoglobin A1c (HbA1c) levels, weight, blood pressure, and lipid profiles (during troglitazone treatment) with corresponding values 6 months after final pioglitazone dose titration. Drug safety was evaluated by review of hepatic enzyme levels and documented reports of side effects. The study cohort consisted of 316 patients in whom pioglitazone therapy was initiated after they had received troglitazone for at least 1 year. Discontinuation of pioglitazone treatment subsequently occurred in 43 patients; in 7 additional patients, no follow-up occurred. We found no significant difference between baseline and follow-up mean HbA1c values. Aspartate aminotransferase levels did not significantly change after 6 months of pioglitazone therapy; however, alanine aminotransferase levels increased by a statistically significant 3.8 U/L (95% confidence interval, 2.6 to 4.9). Pioglitazone treatment was discontinued be...Continue Reading
References
Dec 1, 1988·Diabetes·G M Reaven
May 1, 1995·Diabetes Research and Clinical Practice·Y OhkuboM Shichiri
Mar 1, 1995·American Journal of Hypertension·T OgiharaK Masuo
Nov 3, 1994·The New England Journal of Medicine·J J NolanJ Olefsky
May 22, 1993·Lancet·P H WangT C Chalmers
Jul 29, 1993·The New England Journal of Medicine·P ReichardU Rosenqvist
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Apr 11, 1996·The New England Journal of Medicine·J P DesprésP J Lupien
Mar 27, 1998·The New England Journal of Medicine·S SchwartzJ F Graveline
Sep 4, 1998·Diabetes Care·J B BuseR W Whitcomb
May 20, 1999·Diabetes Care·I E KellyM E Lean
Jun 8, 1999·JAMA : the Journal of the American Medical Association·R C TurnerR R Holman
Aug 12, 1999·The New England Journal of Medicine·R H Knopp
Aug 24, 1999·Annals of Internal Medicine·R A DeFronzo
Apr 13, 2000·Archives of Internal Medicine·UNKNOWN National Task Force on the Prevention and Treatment of Obesity
Jun 17, 2000·Diabetes Care·A B King
Feb 24, 2001·Annals of Internal Medicine·A A ParulkarV A Fonseca
Jun 26, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·C G Gegick, M D Altheimer
Mar 29, 2002·Diabetes Care·Mehmood A KhanJay L Xue
Apr 16, 2002·Clinical Therapeutics·Patrick J BoyleJohn Martin
Jun 7, 2002·The Journal of Clinical Endocrinology and Metabolism·Yoshinori MiyazakiRalph A DeFronzo
Sep 28, 2002·Diabetes Care·Giancarlo VibertiMartin I Freed
Oct 9, 2002·JAMA : the Journal of the American Medical Association·Katherine M FlegalClifford L Johnson
Dec 28, 2002·Diabetes Care·UNKNOWN American Diabetes Association
Mar 1, 2003·Diabetes Care·Paul HoganUNKNOWN American Diabetes Association